

1 Title: Evaluation of immunological responses to third COVID-19 vaccine among people
2 treated with sphingosine receptor-1 modulators and anti-CD20 therapy
3

4 Authors: Ilana Katz Sand MD,¹ Sacha Gnjatic PhD^{2,3,4}, Florian Krammer PhD^{4,5}, Kevin
5 Tuballes², Juan Manuel Carreño⁵, Sammita Satyanarayan MD,¹ Susan Filomena BA,¹
6 Erin Staker BS,¹ Johnstone Tcheou⁵, Aaron Miller MD,¹ Michelle Fabian MD,¹ Neha Safi
7 MD,¹ Jamie Nichols MD,¹ Jasmin Patel MD,¹ Stephen Krieger MD,¹ Stephanie Tankou
8 MD, PhD,¹ Sam Horng MD, PhD,¹ Sylvia Klineova MD,¹ Erin Beck MD, PhD,¹ Miriam
9 Merad MD, PhD,^{2,3} Fred Lublin MD¹

10
11 Affiliations: 1. Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of
12 Neurology, Icahn School of Medicine at Mount Sinai, 2. Precision Immunology Institute,
13 Human Immune Monitoring Center, 3. Department of Oncological Sciences, Icahn School
14 of Medicine at Mount Sinai, New York, NY 10029, 4. Department of Pathology, Icahn
15 School of Medicine at Mount Sinai, New York, NY 10029. 5. Department of Microbiology,
16 Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine
17 Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount
18 Sinai, New York, NY, USA,
19

20 **Corresponding Author:**

21 Ilana Katz Sand, MD
22 Corinne Goldsmith Dickinson Center for Multiple Sclerosis
23 5 E. 98th Street
24 Suite 1138
25 New York, NY 10029
26 ilana.katzsand@mssm.edu
27 212-241-6854
28
29
30

31 **Abstract**

32

33 **Importance:** People living with multiple sclerosis (MS) and other disorders treated with
34 immunomodulatory therapies remain concerned about suboptimal responses to
35 coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding
36 immunological response to third vaccines, particularly with respect to newer virus
37 variants.

38 **Objective:** Evaluate humoral and cellular immune responses to third COVID-19 vaccine
39 dose in people on anti-CD20 therapy and sphingosine 1-phosphate receptor (S1PR)
40 modulators, including Omicron-specific assays.

41 **Design:** Observational study evaluating immunological response to third COVID-19
42 vaccine dose in volunteers treated with anti-CD20 agents, S1PR modulators, and healthy
43 controls. Neutralizing antibodies against USA-WA1/2020 (WA1) and B.1.1.529 (BA.1)
44 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were measured before
45 and after third vaccine. Cellular responses to spike peptide pools generated from WA1
46 and BA.1 were evaluated.

47 **Setting:** Mount Sinai Hospital

48 **Participants:** People treated with anti-CD20 therapy or S1PR modulators and healthy
49 volunteers

50 **Exposure:** Treatment with anti-CD20 therapy, S1PR modulator, or neither

51 **Main outcomes and measures:** Serum neutralizing antibodies and *ex vivo* T cell
52 responses against SARS-CoV-2 antigens.

53 **Results:** This cohort includes 25 participants on anti-CD20 therapy, 12 on S1PR
54 modulators, and 14 healthy controls. Among those on anti-CD20 therapy, neutralizing
55 antibodies to WA1 were significantly reduced compared to healthy controls (ID50% GM
56 post-vaccination of 8.1 ± 2.8 in anti-CD20 therapy group vs 452.6 ± 8.442 healthy
57 controls, $P < 0.0001$) and neutralizing antibodies to BA.1 were below the threshold of
58 detection nearly universally. However, cellular responses, including to Omicron-specific
59 peptides, were not significantly different from controls. Among those on S1PR
60 modulators, neutralizing antibodies to WA1 were detected in a minority, and only 3/12
61 had neutralizing antibodies just at the limit of detection to BA.1. Cellular responses to
62 Spike antigen in those on S1PR modulators were reduced by a factor of 100 compared
63 to controls (median 0.0008% vs. 0.08%, $p < 0.001$) and were not significantly “boosted” by
64 a third injection.

65 **Conclusions and Relevance:** Participants on immunomodulators had impaired antibody
66 neutralization capacity, particularly to BA.1, even after a third vaccine. T cell responses
67 were not affected by anti-CD20 therapies, but were nearly abrogated by S1PR
68 modulators. These results have clinical implications warranting further study.

69

70

71 Manuscript Text

72 **Introduction**

73 Many people receiving treatment with immunomodulatory therapies, including those living
74 with multiple sclerosis (MS), remain apprehensive about COVID-19 risk.

75 Among common therapies for MS, there is high concern with anti-CD20 agents and
76 sphingosine 1-phosphate receptor (S1PR) modulators. Anti-CD20 agents deplete
77 circulating B cells and, to a lesser extent, subsets of CD4 and CD8 cells expressing low
78 levels of CD20.¹ In addition to widespread use in MS, anti-CD20 agents are utilized to
79 treat B cell malignancies and a range of immune-mediated neurological and
80 rheumatologic disorders.² S1PR modulators functionally block S1PR function,
81 sequestering lymphocytes in the lymph nodes and thymus.³ In addition to use in MS, the
82 S1PR modulator ozanimod was recently approved for ulcerative colitis and ponesimod is
83 currently in late stage clinical trials for psoriasis and graft-vs.-host disease.

84
85 Previous data suggest reduced humoral response to the primary vaccine series related
86 to these treatments⁴⁻⁶. Limited evidence suggests preserved cellular response to
87 vaccination with anti-CD20 therapies and reduced response with S1PR modulators.^{7, 8}
88 Epidemiologic studies have suggested worse clinical outcomes with these therapies.⁹

89
90 Here we address the most recent significant questions regarding the production of
91 neutralizing antibodies and cellular immune responses before and after third COVID-19
92 vaccinations in people treated with these immunomodulatory therapies, importantly
93 accounting for the recent Omicron variant.

94

95 **Methods**

96 *Sample*

97 All participants were recruited between Mount Sinai's MS Center and Human Immune
98 Monitoring Center. Eligible participants began treatment with B cell or S1P modulator
99 therapy at least 60 days prior to third vaccine or were healthy volunteers. For this analysis,
100 we included all enrollees who had completed baseline sampling prior to a third injection
101 and a follow-up sample approximately 4 weeks after the third vaccination by early January
102 2022.

103

104 *Assessing Humoral and Cellular Immunity*

105 Microneutralization assays against USA-WA1/2020 (WA1, or wild-type) and B.1.1.529
106 (BA.1, or Omicron variant) SARS-CoV-2 were performed at the Icahn School of Medicine
107 as previously described.¹⁰ Groups were compared by one-way ANOVA with Tukey
108 multiple comparisons. T cell responses were assessed by IFN-gamma ELISPOT using
109 400,000 peripheral blood mononuclear cells pulsed with various antigens (15-mer
110 overlapping peptide pool covering the entire sequence of Spike antigen (both WT and
111 Omicron variants, from Miltenyi Biotec), N & Orf antigens (Bhardwaj, GenScript), long
112 peptides covering the Spike RBD domain (Biosynthesis), recombinant Spike protein (gift
113 from Drs. Herrera and Garforth, Einstein College of Medicine), and control viral peptide
114 pools, DMSO, and PMA+ionomycine, as described.¹¹ Responses were considered
115 positive if >20 spots were detected and at least 2x more than the number of spots to

116 DMSO. Pre-post comparisons were made by Wilcoxon paired t-tests, inter-cohort
117 comparisons by Mann-Whitney t-test.

118

119 **Results**

120 **Table 1** describes 25 participants on B cell therapy, 12 on S1PR modulators, and 14
121 controls.

122

123 **Figure 1** illustrates neutralizing antibody titers. Few on B-cell therapies mounted
124 detectable neutralizing antibodies to WA1 (n=4, 2 just above the limit of detection (LoD)),
125 with some increasing after the third vaccination (n=7, 4 just above the LoD). None had
126 detectable neutralizing antibodies to BA.1 before the third vaccination, and only one
127 converted after third vaccination. Among patients on S1PR modulators, three participants
128 had neutralizing antibodies to BA.1 just at the level of detection post third injection. This
129 contrasts with healthy controls, where a third vaccination resulted in detectable
130 neutralizing antibodies to WA1 (ID50% GM of 59.25 ± 6.536 pre- vs 452.6 ± 8.442 post-
131 vaccination, $P < 0.01$) and BA.1 (ID50% GM of 6.13 ± 1.418 pre- vs 75.71 ± 3.405 post-
132 vaccination, $P < 0.0001$) nearly universally.

133

134 **Figure 2** demonstrates the cellular response to spike peptide pools generated from WA1
135 **(A)** and BA.1 **(B)** SARS-CoV-2. Although there was more variability among those on B
136 cell therapies compared to controls, overall T cell responses were not significantly
137 different between B cell participants and controls. B cell participants showed significantly
138 increased responses to WA1 and BA.1 peptides after a third injection (median 0.04%
139 increase, $p = 0.008$ by Wilcoxon paired test). Responses to WT Spike peptide pool were
140 significantly greater in controls and B cell participants compared to S1PR participants
141 (median 300-450 spots vs. 3 spots out of 400,000 PBMC, $p < 0.0001$). Among S1PR
142 participants, responses were not significantly different before and after third injection
143 (median 0.004% increase). These results were confirmed with the Omicron peptide pool,
144 RBD peptide pool, and Spike full-length protein, though these were generally less reactive
145 in controls as well. Responses to the peptide pool generated from nucleocapsid (N) and
146 open reading frame (ORF) proteins, which reflect naturally occurring immunity rather than
147 vaccine-induced immunity, were not significantly different in MS participants compared to
148 controls. Interestingly, responses to CEFT (cytomegalovirus, Epstein-Barr virus, influenza
149 A virus, *Clostridium tetani*) peptide pools were significantly lower in B cell participants'
150 responses compared to controls.

151

152 **Discussion**

153 Participants on both therapies demonstrated significantly reduced production of
154 neutralizing antibodies, particularly to BA.1, as compared to controls. Cellular immune
155 responses to vaccination were similar among those on B cell therapies to controls and
156 increased after a third vaccination. However, S1P participants demonstrated less robust
157 cellular responses. Driving the lack of significant increase among S1P participants is that
158 there were very few “converts” after the third vaccination. The cellular response
159 increased with a third vaccination among those who had a measurable response to their
160 first two injections, but did not increase for patients who never responded to the first two

161 injections. This observation has significant consequences for expected responses to
162 additional vaccines among those on S1PR modulators.

163
164 Timing of therapy initiation may play a role in vaccine response. The lone B cell participant
165 with a high level of neutralizing antibodies to BA.1 after the third vaccination received the
166 first vaccinations prior to starting therapy, though notably two others who started therapy
167 after the first vaccinations did not develop neutralizing antibodies to BA.1 after the third
168 vaccine. Of three S1P participants with neutralizing antibodies to BA.1 just at LOD, two
169 received their first injections prior to starting therapy. These are important preliminary
170 observations that will be relevant to those with new diagnoses or needing to change
171 therapy going forward.

172
173 Strengths of our study include the presence of a control group and the study of S1PR
174 modulators in addition to B cell therapy. We have assessed the levels of neutralizing
175 antibodies, which reflect the effectiveness of the humoral immune response and
176 represent a mechanistic correlate of protection against SARS-CoV-2,^{12, 13} and measured
177 cellular immunity. We have also studied Omicron-specific assays, which more accurately
178 reflect the current circulating strains.

179
180 Our study is limited by its small size. The cohort includes only one participant over age
181 65 because of the timing of enrollment (many of those over 65 had already received a
182 third vaccine when enrollment began). We did not quantify the relative contribution of CD8
183 vs. CD4 T cell responses, though target antigen formulations used in our assays suggest
184 that the third dose is better at increasing CD8 than CD4 T cells.¹⁴ Study design did not
185 permit correlation to clinical outcomes.

186
187 Future directions include assessing durability of vaccine responses over time, studying
188 the impact of natural infection with new variants, and most importantly, correlation with
189 clinical outcomes. For those on S1PR modulators, future studies could consider brief
190 cessation of therapy to aim for an improved response to additional injection, weighing
191 potential benefits and risks of such a strategy.

192
193
194
195 **Acknowledgments:** The authors would like to thank the Fishman family for generously
196 supporting this work, as well our patients at the CGD MS Center who graciously donated
197 their time and samples to participate in this study.

198
199 SG was partially supported by NIH grants and contracts CA224319, DK124165,
200 75N91020R00055, CA263705, and CA196521.

201
202 Work in the Krammer laboratory was partially funded by the NIAID Collaborative Influenza
203 Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, the Centers of
204 Excellence for Influenza Research and Surveillance (CEIRS, contract #
205 HHSN272201400008C) and the Serological Sciences Network (SeroNet) in part with
206 Federal funds from the National Cancer Institute, National Institutes of Health, under

207 Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this
208 publication does not necessarily reflect the views or policies of the Department of Health
209 and Human Services, nor does mention of trade names, commercial products or
210 organizations imply endorsement by the U.S. Government.

211
212 **Disclosures:**

213 SG reports past consultancy or advisory roles for Merck and OncoMed; research funding
214 from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, EMD Serono,
215 Pfizer, Regeneron Pharmaceuticals, and Takeda, all unrelated to the current work.

216
217 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to
218 SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list
219 Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market
220 serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer
221 (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and
222 Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of
223 SARS-CoV-2.

224
225 **References**

- 226 1. Bar-Or A, O'Brien SM, Sweeney ML, Fox EJ, Cohen JA. Clinical Perspectives on the Molecular and
227 Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. *CNS Drugs*. Sep
228 2021;35(9):985-997. doi:10.1007/s40263-021-00843-8
- 229 2. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances
230 and mechanistic insights. *Nat Rev Drug Discov*. Mar 2021;20(3):179-199. doi:10.1038/s41573-020-
231 00092-2
- 232 3. McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and
233 other conditions. *Lancet*. Sep 25 2021;398(10306):1184-1194. doi:10.1016/s0140-6736(21)00244-0
- 234 4. Satyanarayan S, Safi N, Sorets T, et al. Differential antibody response to COVID-19 vaccines
235 across immunomodulatory therapies for multiple sclerosis. *Multiple Sclerosis and Related Disorders*.
236 doi:10.1016/j.msard.2022.103737
- 237 5. Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 Vaccine Response in People with
238 Multiple Sclerosis. *Ann Neurol*. Jan 2022;91(1):89-100. doi:10.1002/ana.26251
- 239 6. Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients
240 treated with disease modifying therapies. *EBioMedicine*. Oct 2021;72:103581.
241 doi:10.1016/j.ebiom.2021.103581
- 242 7. Gadani SP, Reyes-Mantilla M, Jank L, et al. Discordant humoral and T cell immune responses to
243 SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. *EBioMedicine*. Nov
244 2021;73:103636. doi:10.1016/j.ebiom.2021.103636
- 245 8. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following
246 SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med*. Nov
247 2021;27(11):1990-2001. doi:10.1038/s41591-021-01507-2
- 248 9. Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 Severity in Multiple Sclerosis: Putting
249 Data Into Context. *Neurol Neuroimmunol Neuroinflamm*. Jan
250 2022;9(1)doi:10.1212/nxi.0000000000001105
- 251 10. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against
252 SARS-CoV-2 Omicron. *Nature*. 2022/02/01 2022;602(7898):682-688. doi:10.1038/s41586-022-04399-5

- 253 11. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-
254 antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
255 *Clin Cancer Res.* Dec 1 2012;18(23):6497-508. doi:10.1158/1078-0432.Ccr-12-2189
256 12. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of
257 immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine.* 2021/07/01
258 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
259 13. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273
260 COVID-19 vaccine efficacy clinical trial. *Science.* 2022;375(6576):43-50.
261 doi:doi:10.1126/science.abm3425
262 14. Gnjjatic S, Atanackovic D, Matsuo M, et al. Cross-presentation of HLA class I epitopes from
263 exogenous NY-ESO-1 polypeptides by nonprofessional APCs. *J Immunol.* Feb 1 2003;170(3):1191-6.
264 doi:10.4049/jimmunol.170.3.1191

265
266

Table 1 - Clinical Characteristics (n=51)				
		Control (n=14)	S1P (n=12)	Bcell (n=25)
Age (years), median (range)		31 (24-61)	42 (31-69)	49 (26-65)
Sex				
	Male, n (% total)	9 (64%)	7 (58%)	12 (48%)
	Female, n (% total)	5 (36%)	5 (42%)	13 (52%)
Race				
	White, n (% total)	12 (85%)	11(92%)	22 (88%)
	Black, n (% total)	0(0%)	1 (8%)	0 (0%)
	Asian, n (% total)	1 (7%)	0 (0%)	2 (8%)
	Biracial, n (% total)	1 (7%)	0 (0%)	1 (4%)
Ethnicity				
	Hispanic, n (% total)	2 (14%)	1 (8%)	2 (8%)
	Non-Hispanic, n (% total)	12 (86%)	11(92%)	23 (92%)
Disease Category				
	none, n (% total)	13(93%)	0 (0%)	0 (0%)
	RRMS, n (% total)	1 (7%)	11 (92%)	21 (84%)
	SPMS, n (% total)	0 (0%)	1 (8%)	1 (4%)
	PPMS, n (% total)	0 (0%)	0 (0%)	2 (8%)
	MOG, n (% total)	0 (0%)	0 (0%)	1 (4%)
Disease Modifying Therapy (DMT)				
	none, n (% total)	13(93%)	0 (0%)	0 (0%)
	teriflunomide, n (% total)	1 (7%)	0 (0%)	0 (0%)
S1P Class				
	fingolimod, n (% total)	0 (0%)	8 (67%)	0 (0%)
	siponimod, n (% total)	0 (0%)	2 (17%)	0 (0%)
	ozanimod, n (% total)	0 (0%)	2 (17%)	0 (0%)
Anti-CD20 Class				
	rituximab, n (% total)	0 (0%)	0 (0%)	2 (8%)
	ocrelizumab, n (% total)	0 (0%)	0 (0%)	22 (88%)
	ofatumumab, n (% total)	0 (0%)	0 (0%)	1 (4%)
DMT duration (days), median (range)		n/a*	1471 (69-3888)	1185 (112-2629)
Vaccine Type				
	Pfizer, n (% total)	11(79%)	5 (42%)	13 (52%)
	Moderna, n (% total)	3 (21%)	5 (42%)	12 (48%)
	J&J, n (% total)	0 (0%)	2 (16%)	0 (0%)
Vaccine Interval**				
	days(median, range)	279 (242-317)	183 (147-257)	207 (48-287)
Immunological Testing				
	T0 (pre-booster), days- (median,range)	0 (0-7)	5 (0-21)	3 (0-21)
	T4 (4 weeks post booster)- days (median,range)	28 (26-45)	28 (23-37)	29 (22-39)
Covid-19 Infection History***				
	None, n (% total)	11 (79%)	12 (100%)	19 (76%)
	Suspected, n (% total)	2 (14%)	0 (0%)	3 (12%)
	Confirmed, n (% total)	1 (7%)	0%	3 (12%)

*DMT duration defined as time from DMT start to booster date for all patients. Of note, 1 control patient was on Aubagio (active comparator) and time from dmt start for that patient was 2694 days.


** Vaccine interval is defined by the time between the 2nd vaccination and 3rd vaccination for patients receiving Pfizer or Moderna vaccines, and is defined by time between 1st vaccination and 2nd vaccination for patients receiving J&J.

***Covid-19 Infection was defined as suspected or confirmed covid-19 prior to 3rd vaccination (or 2nd vaccination for patients with J&J). Controls (n=3), S1P (n=0), Anti-CD20 (n=6).

8

268 **Figure 1. Neutralizing antibodies. Neutralization expressed as the inhibitory dilution**
 269 **50% (ID_{50}) of sera against USA-WA1/2020 (WT, shown in A) and B.1.1.529 (Omicron,**
 270 **shown in B) SARS-CoV-2 live viruses in the three groups: B cell, S1P, and healthy**
 271 **controls. Group comparisons performed using a One-way ANOVA with Tukey multiple**
 272 **comparisons; ns: not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$**
 273

Figure 1



274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289

Figure 2. Cellular response. Number of positive interferon (IFN)- γ spots (log scale) out
 of 400,000 PBMC for the three groups: B cell, S1P, and healthy controls against the
 indicated antigens: Spike WT peptide pool WA1 (A); Spike omicron variant peptide pool
 (B); Spike full-length protein (C); long peptide pool covering Spike RBD domain (D);
 positive control viral peptide pool CEFT [from CMV, EBV, influenza, and tetanus] (E);
 SARS-CoV-2 N & Orf peptide pool (F); and assay control PMA/Ionomycin, out of 40,000
 PBMCs (G). Intergroup comparisons by Mann-Whitney t-test in bold, pre-post
 comparisons by Wilcoxon paired test; ns: not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,
 **** $p < 0.0001$.

